Researchers have revealed the mechanism underlying GPCR function using a GPS nuclear magnetic resonance (NMR) technique.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Evotec's insights into GPCRs and waveRAPID technology reveal new opportunities in drug discovery, focusing on orphan ...

A Monash University study of almost 400,000 people, published in the journal Cardiovascular Research , is the first to ...